Rebekah Kim, MD
Colon & Rectal Surgery · Fairfax, VANPI 1841510534
Payments from drug & device makers
What this record shows
Medical Device Business Services, Inc. accounts for 67.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $1,513 and has fallen 88.7% since, to $171 in 2024.
Across 20 payments — averaging $110.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1K
- Gilead$301
- Myriad Genetic Laboratories, Inc.$130
- Johnson & Johnson$113
- Medtronic$41
- SK Life Science, Inc.$38
- plus $92 from 4 others
What the payments were for
- Travel & lodging$1,22456%
- Food & beverage$98144%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 8 | $1,490 |
| Gilead | 3 | $301 |
| Myriad Genetic Laboratories, Inc. | 1 | $130 |
| Johnson & Johnson | 1 | $113 |
| Medtronic | 1 | $41 |
| SK Life Science, Inc. | 2 | $38 |
| Stryker | 1 | $25 |
| AbbVie | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ECHELON FLEX Stapler$1,327
- Vemlidy$219
- myRisk$130
- Echelon Flex$113
- Echelon Circular$113
- ECHELON ENDOPATH$113
How this compares
$2,205 in reported general payments places this provider in the 55th percentile of 46 colon & rectal surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CholestyramineCholestyramine (With Sugar) | 23 | $1,349 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 22 | $584 |
| Neomycin Sulfate | 12 | $54 |
| Metronidazole | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Fairfax
- Kimberly MatzieFairfax$28K
- Othon WiltzFairfax$4K
- Paul SavocaFairfax$3K
- Katherine KhalifehFairfax$2K
- Christina ChengFairfax$2K
- John TillouFairfax$1K
- Daniel OtchyFairfax$289
- Caroline SanchezFairfax$247
- Anna KataFairfax$171
- Andrew VorenbergRichmond$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.